Replimune (REPL) Change in Account Payables (2017 - 2026)
Replimune (REPL) posted Change in Account Payables of $956000.0 for Q1 2026, up 230.96% sequentially from -$730000.0 in Q4 2025, and down 81.76% YoY from $5.2 million in Q1 2025.
Powered by 
Analysis
Replimune (REPL) Change in Account Payables (2017 - 2026) Analysis & Trends
Replimune has reported Change in Account Payables for 10 years, with the latest figure at $956000.0 in Q1 2026.
- Quarterly Change in Account Payables fell 81.76% year-over-year to $956000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.9 million (down 149.68% YoY) and the FY2026 annual result came in at -$4.9 million, down 149.68% from the prior year.
- Change in Account Payables rose to $956000.0 in Q1 2026 per REPL's latest filing, from -$730000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $7.5 million in Q3 2024 and troughed at -$8.9 million in Q3 2025.
- A 5-year average of $242000.0 and a median of -$213000.0 in 2023 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2022 and 2024: Change in Account Payables sank 476.92% in 2022, then soared 3604.23% in 2024.
- Over 5 years, Change in Account Payables stood at -$341000.0 in 2022, then slumped by 39.59% to -$476000.0 in 2023, then sank by 141.39% to -$1.1 million in 2024, then jumped by 36.47% to -$730000.0 in 2025, then jumped by 230.96% to $956000.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered $956000.0, -$730000.0, and -$8.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Replimune | 1.46 Bn | 1.46 Bn | - | -2.33 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.33 Mn |
| Mar 31, 2026 | 956,000.00 |
| Dec 31, 2025 | -730,000.00 |
| Sep 30, 2025 | -8.93 Mn |
| Jun 30, 2025 | 3.77 Mn |
| Mar 31, 2025 | 5.24 Mn |
| Dec 31, 2024 | -1.15 Mn |
| Sep 30, 2024 | 7.46 Mn |
| Jun 30, 2024 | -1.62 Mn |
| Mar 31, 2024 | -1.29 Mn |
| Dec 31, 2023 | -476,000.00 |
| Sep 30, 2023 | -213,000.00 |
| Jun 30, 2023 | -816,000.00 |
| Mar 31, 2023 | 1.62 Mn |
| Dec 31, 2022 | -341,000.00 |
| Sep 30, 2022 | -197,000.00 |
| Jun 30, 2022 | 895,000.00 |
| Mar 31, 2022 | -75,000.00 |
| Dec 31, 2021 | 443,000.00 |
| Sep 30, 2021 | 684,000.00 |